Immunoprecise Antibodies Ltd
XTSX:IPA
Intrinsic Value
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of IPA.
Immunoprecise Antibodies Ltd's market capitalization is 161.4m CAD.
IPA stock price is 6.5 CAD.
IPA.
IPA. Open DCF Valuation
IPA. Open Relative Valuation
IPA has upside potential of 85% compared to the average analyst price target.
Open Wall St Estimates
IPA has negative Operating Income for the last twelve months.
IPA has negative Net Income for the last twelve months.
IPA's ROE (Return on Equity) for the past 12 months is negative and is equal to -36%.
IPA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -71%.
IPA has positive Gross Profit for the last twelve months.
IPA has negative Free Cash Flow for the last twelve months.
IPA's D/E (Debt to Equity) is very low and is equal to 0.01.
IPA has negative three-year average ROE (Return on Equity): -36%. The company is not efficient at transforming stockholders' equity into net income.
IPA has negative three-year average ROIC (Return on Invested Capital): -71%. The company is not efficient at using invested capital to generate operating income.
IPA's short-term assets (41m CAD) exceed its short-term liabilties (7m CAD).
IPA's long-term assets (56m CAD) exceed its long-term liabilties (9m CAD).
IPA has negative Net Debt. This means that the company has more cash and short-term investments (33m CAD) than debt (540k CAD).
IPA's Altman Z-Score is very high and is equal to 11.83.
IPA doesn't generate enough operating income (-15m CAD) to safely cover interest payments on its debt (160k CAD).
Fundamental Analysis
Immunoprecise Antibodies Ltd
Balance Sheet Decomposition
Immunoprecise Antibodies Ltd
| Current Assets | 40.6m |
| Cash & Short-Term Investments | 33m |
| Receivables | 3.5m |
| Other Current Assets | 4.1m |
| Non-Current Assets | 15.9m |
| Long-Term Investments | 100k |
| PP&E | 3.6m |
| Intangibles | 4.5m |
| Other Non-Current Assets | 7.7m |
| Current Liabilities | 7.1m |
| Other Current Liabilities | 7.1m |
| Non-Current Liabilities | 1.6m |
| Long-Term Debt | 540k |
| Other Non-Current Liabilities | 1.1m |
Earnings Waterfall
Immunoprecise Antibodies Ltd
|
Revenue
|
19m
CAD
|
|
Cost of Revenue
|
-8.6m
CAD
|
|
Gross Profit
|
10.5m
CAD
|
|
Operating Expenses
|
-25.5m
CAD
|
|
Operating Income
|
-15m
CAD
|
|
Other Expenses
|
-2.1m
CAD
|
|
Net Income
|
-17.1m
CAD
|
Free Cash Flow Analysis
Immunoprecise Antibodies Ltd
IPA Profitability Score
Profitability Due Diligence
Immunoprecise Antibodies Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Immunoprecise Antibodies Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
IPA Solvency Score
Solvency Due Diligence
Immunoprecise Antibodies Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Immunoprecise Antibodies Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IPA Price Targets Summary
Immunoprecise Antibodies Ltd
According to Wall Street analysts, the average 1-year price target for
IPA
is 12 CAD
.
Shareholder Return
IPA Price
Immunoprecise Antibodies Ltd
| Average Annual Return | 260.86% |
| Standard Deviation of Annual Returns | 401.71% |
| Max Drawdown | -81% |
| Market Capitalization | 161.4m CAD |
| Shares Outstanding | 24 836 700 |
| Percentage of Shares Shorted | 0.29% |
Company Profile
Immunoprecise Antibodies Ltd
Country
Industry
Market Cap
Dividend Yield
Description
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia and currently employs 73 full-time employees. The firm is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The firm offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.
You don't have any saved screeners yet
